Temporal trends in the clinical presentation, management, and outcomes of children with congenital cytomegalovirus infection.

IF 2.9 3区 医学 Q1 PEDIATRICS
Jitka Bolchová, Despoina Gkentzi, Roberto Pedrero Tomé, Garyfallia Syridou, Antoni Noguera-Julián, María Ríos-Barnés, Serena Salomé, Francesco Raimondi, Serena Villaverde, Fernando Baquero-Artigao, Paula Rodriguez-Molino, Danilo Buonsenso, Laura Martino, Beatriz Álvarez-Vallejo, Jesús Saavedra, Yves Fougere, Hermione Lyall, Ina Foulon, Horst Buxmann, Simona Zanette, Olga Tsiatsiou, Jessica Wan, Daniel Blázquez-Gamero, Vana Papaevangelou
{"title":"Temporal trends in the clinical presentation, management, and outcomes of children with congenital cytomegalovirus infection.","authors":"Jitka Bolchová, Despoina Gkentzi, Roberto Pedrero Tomé, Garyfallia Syridou, Antoni Noguera-Julián, María Ríos-Barnés, Serena Salomé, Francesco Raimondi, Serena Villaverde, Fernando Baquero-Artigao, Paula Rodriguez-Molino, Danilo Buonsenso, Laura Martino, Beatriz Álvarez-Vallejo, Jesús Saavedra, Yves Fougere, Hermione Lyall, Ina Foulon, Horst Buxmann, Simona Zanette, Olga Tsiatsiou, Jessica Wan, Daniel Blázquez-Gamero, Vana Papaevangelou","doi":"10.1007/s00431-026-07485-2","DOIUrl":null,"url":null,"abstract":"<p><p>Congenital cytomegalovirus (cCMV) is the most common congenital infection and a leading cause of sensorineural hearing loss as well as neurodevelopmental impairment. In recent years, awareness, screening, and management strategies for cCMV have evolved. This study aimed to assess temporal changes in the clinical presentation, treatment, and outcomes of children diagnosed with cCMV infection. We conducted a retrospective cohort analysis using data from the CCMVnet registry ( www.ccmvnet.org ), an international multicenter database collecting anonymized data on children with confirmed cCMV infection. A total of 1653 patients diagnosed between 2011 and 2024 were included and divided into two cohorts: 2011-2016 (n = 566) and 2017-2024 (n = 1087). The year 2017 was selected as a pragmatic cutoff, corresponding to the year of publication of the European expert consensus statement on congenital CMV. Children were identified through antenatal, clinical, hearing-related, and newborn screening pathways. Symptomatic cCMV at birth was defined by the presence of at least one predefined clinical, laboratory, hearing, or neuroimaging finding based on previously published criteria. A comparative analysis between two distinct time periods was conducted, encompassing neonatal clinical findings, neuroimaging results, treatment strategies, and long-term outcomes. Newborns classified as symptomatic at birth decreased in the more recent cohort, from 49.2% in P1 to 44.2% in P2 (p = 0.07). The use of intravenous ganciclovir decreased from 7.3% to 2.8% (p < 0.001), while the use of oral valganciclovir alone increased from 43.8% to 78.7% (p < 0.001). Differences in long-term outcomes were observed between the two periods, with motor impairment at 12 months decreasing from 16.5% to 6.2% (p < 0.001) and any long-term sequelae at 36 months decreasing from 40.0% to 31.0% (p = 0.05).</p><p><strong>Conclusion: </strong> This study highlights temporal differences in the clinical spectrum, management, and outcomes of children with congenital CMV infection in Europe. The higher proportion of asymptomatic and mildly symptomatic children in the latter period may reflect changes in maternal and neonatal screening practices. The observed temporal differences provide insight into the evolving clinical landscape of cCMV diagnosis and management, while their underlying causes cannot be determined from the present data.</p><p><strong>What is known: </strong>• Congenital cytomegalovirus (cCMV) infection is the leading infectious cause of sensorineural hearing loss and neurodevelopmental impairment in children. • Clinical management of cCMV has evolved substantially over the last decade, particularly following the publication of the European expert consensus statement in 2017 and alongside expanding screening strategies.</p><p><strong>What is new: </strong>• In our cohort, children diagnosed with cCMV after 2017 presented with milder clinical manifestations and experienced fewer long-term sequelae than those diagnosed before 2017. • Temporal changes in diagnostic pathways, treatment practices, and clinical outcomes were observed between the two study periods.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"185 11","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668897/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00431-026-07485-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Congenital cytomegalovirus (cCMV) is the most common congenital infection and a leading cause of sensorineural hearing loss as well as neurodevelopmental impairment. In recent years, awareness, screening, and management strategies for cCMV have evolved. This study aimed to assess temporal changes in the clinical presentation, treatment, and outcomes of children diagnosed with cCMV infection. We conducted a retrospective cohort analysis using data from the CCMVnet registry ( www.ccmvnet.org ), an international multicenter database collecting anonymized data on children with confirmed cCMV infection. A total of 1653 patients diagnosed between 2011 and 2024 were included and divided into two cohorts: 2011-2016 (n = 566) and 2017-2024 (n = 1087). The year 2017 was selected as a pragmatic cutoff, corresponding to the year of publication of the European expert consensus statement on congenital CMV. Children were identified through antenatal, clinical, hearing-related, and newborn screening pathways. Symptomatic cCMV at birth was defined by the presence of at least one predefined clinical, laboratory, hearing, or neuroimaging finding based on previously published criteria. A comparative analysis between two distinct time periods was conducted, encompassing neonatal clinical findings, neuroimaging results, treatment strategies, and long-term outcomes. Newborns classified as symptomatic at birth decreased in the more recent cohort, from 49.2% in P1 to 44.2% in P2 (p = 0.07). The use of intravenous ganciclovir decreased from 7.3% to 2.8% (p < 0.001), while the use of oral valganciclovir alone increased from 43.8% to 78.7% (p < 0.001). Differences in long-term outcomes were observed between the two periods, with motor impairment at 12 months decreasing from 16.5% to 6.2% (p < 0.001) and any long-term sequelae at 36 months decreasing from 40.0% to 31.0% (p = 0.05).

Conclusion:  This study highlights temporal differences in the clinical spectrum, management, and outcomes of children with congenital CMV infection in Europe. The higher proportion of asymptomatic and mildly symptomatic children in the latter period may reflect changes in maternal and neonatal screening practices. The observed temporal differences provide insight into the evolving clinical landscape of cCMV diagnosis and management, while their underlying causes cannot be determined from the present data.

What is known: • Congenital cytomegalovirus (cCMV) infection is the leading infectious cause of sensorineural hearing loss and neurodevelopmental impairment in children. • Clinical management of cCMV has evolved substantially over the last decade, particularly following the publication of the European expert consensus statement in 2017 and alongside expanding screening strategies.

What is new: • In our cohort, children diagnosed with cCMV after 2017 presented with milder clinical manifestations and experienced fewer long-term sequelae than those diagnosed before 2017. • Temporal changes in diagnostic pathways, treatment practices, and clinical outcomes were observed between the two study periods.

先天性巨细胞病毒感染儿童的临床表现、治疗和预后的时间趋势。
先天性巨细胞病毒(cCMV)是最常见的先天性感染,也是引起感音神经性听力损失和神经发育障碍的主要原因。近年来,对cCMV的认识、筛查和管理策略发生了变化。本研究旨在评估诊断为cCMV感染的儿童的临床表现、治疗和结局的时间变化。我们使用CCMVnet注册表(www.ccmvnet.org)的数据进行了回顾性队列分析,CCMVnet是一个国际多中心数据库,收集了确诊cCMV感染儿童的匿名数据。共纳入2011年至2024年间诊断的1653例患者,并分为两个队列:2011-2016 (n = 566)和2017-2024 (n = 1087)。2017年被选为务实的截止年份,与欧洲先天性巨细胞病毒专家共识声明的出版年份相对应。通过产前、临床、听力相关和新生儿筛查途径确定儿童。出生时症状性cCMV的定义是根据先前公布的标准至少存在一项预定义的临床、实验室、听力或神经影像学发现。在两个不同的时间段之间进行了比较分析,包括新生儿临床表现,神经影像学结果,治疗策略和长期结果。在最近的队列中,出生时被分类为有症状的新生儿从P1的49.2%下降到P2的44.2% (p = 0.07)。静脉注射更昔洛韦的使用率从7.3%下降到2.8% (p)。结论:本研究突出了欧洲先天性巨细胞病毒感染儿童的临床谱、管理和结局的时间差异。后期无症状和轻度症状儿童比例较高可能反映了孕产妇和新生儿筛查做法的变化。观察到的时间差异为cCMV诊断和管理的临床发展提供了见解,而其根本原因无法从目前的数据中确定。已知情况:•先天性巨细胞病毒(cCMV)感染是儿童感音神经性听力损失和神经发育障碍的主要感染性原因。•cCMV的临床管理在过去十年中发生了重大变化,特别是在2017年欧洲专家共识声明发布之后以及扩大筛查策略之后。新发现:•在我们的队列中,与2017年之前诊断的cCMV相比,2017年之后诊断为cCMV的儿童临床表现较轻,长期后遗症较少。•在两个研究期间观察到诊断途径、治疗方法和临床结果的时间变化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.90
自引率
2.80%
发文量
367
审稿时长
3-6 weeks
期刊介绍: The European Journal of Pediatrics (EJPE) is a leading peer-reviewed medical journal which covers the entire field of pediatrics. The editors encourage authors to submit original articles, reviews, short communications, and correspondence on all relevant themes and topics. EJPE is particularly committed to the publication of articles on important new clinical research that will have an immediate impact on clinical pediatric practice. The editorial office very much welcomes ideas for publications, whether individual articles or article series, that fit this goal and is always willing to address inquiries from authors regarding potential submissions. Invited review articles on clinical pediatrics that provide comprehensive coverage of a subject of importance are also regularly commissioned. The short publication time reflects both the commitment of the editors and publishers and their passion for new developments in the field of pediatrics. EJPE is active on social media (@EurJPediatrics) and we invite you to participate. EJPE is the official journal of the European Academy of Paediatrics (EAP) and publishes guidelines and statements in cooperation with the EAP.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书